{
  "id": 11172707,
  "title": "STAT+: Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy",
  "url": "https://urgent.news/2026/10/01/stat-why-a-huntingtons-patient-isnt-fazed-by-the-waning-effect-of",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-01T10:30:00.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/2026/10/01/huntingtons-disease-uniqure-drug-study-results-patients/"
  },
  "original_language": "en",
  "account": "Lauren Holder, an advocate for the Huntington's disease community, shared her thoughts on UniQure's gene therapy clinical update. The treatment, known as AMT-130, demonstrated a 44% reduction in disease progression over a four-year period in 12 treated patients. However, the effect of AMT-130 appeared to diminish from the third to fourth year, leading to some questions about the therapy's long-term durability. While this decline in treatment efficacy may be concerning, UniQure has not expressed alarm over the issue.",
  "summary": "Questions about the durability of an experimental Huntington's disease therapy matter to Wall Street. They matter less to those directly affected by the disease.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}